NIH-funded research NIH-funded research

Understanding heart function and structure in patients with primary aldosteronism

Official title: (Administrative Supplement) Cardiac Perfusion, Structure, and Function across the Primary Aldosteronism Spectrum

Funded at Brigham and Women's Hospital · NIH-11200687 · Data updated 2026-11-12

This study is looking at how primary aldosteronism impacts heart health in people with heart failure that still pumps well, and it will explore how a medication called spironolactone might help improve their heart function and structure.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionBrigham and Women's Hospital
NIH-funded
Lab location1 site (Boston, United States)
Project startApril 15, 2022
Project endMarch 31, 2027
Funding year2025
Award (this year)$75,460
NIH project number3K23HL159279-04S1
Project IDNIH-11200687 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with primary aldosteronism, particularly those experiencing heart failure with preserved ejection fraction.

Less likely to help

Patients without primary aldosteronism or those not experiencing heart-related issues may not benefit from this research.

What this research studies

This research investigates how primary aldosteronism affects heart function and structure, particularly in patients with heart failure with preserved ejection fraction (HFpEF). It aims to explore the mechanisms by which mineralocorticoid receptor antagonists, like spironolactone, can improve heart health in these patients. The study will involve assessing cardiac perfusion, structure, and function through advanced imaging techniques and clinical evaluations. By understanding these relationships, the research seeks to identify better treatment strategies for those affected by this condition.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment options for patients with heart failure and primary aldosteronism, potentially reducing cardiovascular risks.

How similar studies have gone: Previous research has shown promising results with mineralocorticoid receptor antagonists in similar patient populations, indicating potential for success in this area.

Where this research is happening

  • Brigham and Women's Hospital
    Boston, United States
    Active

Researchers

  • Principal investigator: Brown, Jenifer Michelle — Brigham and Women's Hospital
  • Study coordinator: Brown, Jenifer Michelle

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.